Scarica l'app Stockscreener
4.815
6.19%
0.315
Precedente Chiudi:
$4.50
Aprire:
$4.58
Volume 24 ore:
239.26K
Relative Volume:
0.26
Capitalizzazione di mercato:
$358.79M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-8.5982
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
+14.59%
1M Prestazione:
+15.42%
6M Prestazione:
-2.88%
1 anno Prestazione:
+27.26%
Intervallo 1D:
$4.5216
$4.86
Intervallo di 1 settimana:
$4.051
$4.86
Portata 52W:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Confronta CRVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.815 | 336.99M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.80 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.50 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.42 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.68 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.40 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Can volume confirm reversal in Corvus Pharmaceuticals Inc.Long Setup & Risk Controlled Daily Trade Plans - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Is it time to cut losses on Corvus Pharmaceuticals Inc.July 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Can volume confirm reversal in Corvus Pharmaceuticals Inc. [Rate Cut]Long-Term Growth Plans - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.Long-Term Safety Investment Analysis Report - Newser
Corvus Pharmaceuticals and the 2025 Catalysts for Soquelitinib: A Dual-Target Biotech Play - AInvest
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
Does Corvus Pharmaceuticals Inc. qualify in momentum factor screeningFree High Accuracy Alerts for ROI Traders - Newser
Corvus Pharmaceuticals’ Earnings Call Highlights Progress - TipRanks
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Long term hold vs stop loss in Corvus Pharmaceuticals Inc.Watchlist Summary for Active Day Traders - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyFree Pattern Alert With ROI Driven Strategy - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityStrong Balance Sheet Candidates - thegnnews.com
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesMarket Correction Proof Stock Screening Analysis - Newser
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.Smart Risk Strategy with Entry Optimization - Newser
Published on: 2025-08-11 02:13:29 - Newser
Momentum divergence signals in Corvus Pharmaceuticals Inc. chartFree Triple Digit Return Stock Predictions - Newser
Is Corvus Pharmaceuticals Inc. stock ready for a breakoutTrend Analysis for Safer Market Entries - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.Free Daily Growth Stock Pick Reports - Newser
Is Now a Good Time to Reenter Corvus Pharmaceuticals Inc.Scalable Portfolio Growth Suggestions Released - beatles.ru
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
Real time pattern detection on Corvus Pharmaceuticals Inc. stockTechnical Insight Guide for Safer Trades - Newser
Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window - MSN
Traders Watching For Reversal Pattern in Corvus Pharmaceuticals Inc.AI Trading Suggestions With Accuracy Focus Released - metal.it
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Free Pattern Detection for Entry Confirmation - Newser
What recovery options are there for Corvus Pharmaceuticals Inc.Real Chart Based Opportunity Identification - Newser
Transcript : Corvus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Can technical indicators confirm Corvus Pharmaceuticals Inc.’s reversalFree Short Term Setup With Predictive Chart - Newser
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat By Investing.com - Investing.com South Africa
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat - Investing.com
Corvus Pharmaceuticals Inc (CRVS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Published on: 2025-08-08 00:04:14 - Newser
Corvus Pharmaceuticals Reports Q2 2025 Progress and Financials - TipRanks
Corvus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):